Kornimate/medical-research-clean huggingface dataset:
periodontal status and pregnancy or delivery complications in type 1 diabetes mellitus pregnant women

Conditions: Periodontal Diseases; Periodontitis; Pregnancy Complications; Pregnancy in Diabetic; Diabetes Mellitus, Type 1; Delivery Complication

Summary: the results of contemporary studies suggest an association between inflammatory periodontal disease and pregnancy and delivery complications. the aim of this study was to assess the association between periodontal disease, clinical periodontal parameters and pregnancy or delivery complications in type 1 diabetes mellitus and non-diabetic pregnant women.

the results of contemporary studies suggest an association between inflammatory periodontal disease and pregnancy and delivery complications. the aim of this study was to assess the association between periodontal disease, clinical periodontal parameters and pregnancy or delivery complications in type 1 diabetes mellitus and non-diabetic pregnant women. methods: 15 type 1 diabetes mellitus and 15 non-diabetic primiparous women were enrolled in the prospective "case-control" study. investigators compared periodontal status, levels of glycosylated haemoglobin (hba1c), high sensitivity c-reactive protein (hs-crp), gestational week of birth, birth weight of a newborn and pregnancy or delivery complications (c-section, pre-eclampsia) between the groups.

Eligibility criteria:
inclusion criteria: * healthy pregnant women * pregnant women with diabetes mellitus type 1 * healthy pregnant women with signs of periodontal disease * pregnant women with diabetes mellitus type 1 and signs of periodontal disease exclusion criteria: * smokers * former smokers who had stopped smoking less than five years before participation * pregnant women with other systemic diseases

Keywords: periodontal disease type 1 diabetes mellitus c-section gestational week of birth
clarifix cryoablation clinical study

Conditions: Rhinitis

Summary: this is a single-arm pilot study designed to evaluate the feasibility of cryoablation in the nasal passageway, using the clarifix device, to reduce the symptoms of chronic rhinitis.

this is a small, prospective, multicenter, single-arm, self-controlled interventional feasibility study to evaluation cryoablation in the nasal passage as a treatment for chronic rhinitis. the clarifix device is fda-cleared device with the intended use for the destruction of unwanted tissue during surgical procedures, including in adults with chronic rhinitis.

Eligibility criteria:
inclusion criteria: 1. subject is \>21 years of age 2. subject has had moderate to severe symptoms of rhinorrhea and/or nasal congestion for \>3 months (rtnss rating of 2 or 3) 3. subject has signed irb-approved informed consent form exclusion criteria: 1. subject has clinically significant anatomic obstructions that limit access to the posterior nose including severe septal deviation, nasal polyps, and sinonasal tumor 2. subject has a septal perforation 3. subject has had prior sinus or nasal surgery that significantly alters the anatomy of the posterior nose 4. subject has had prior head or neck irradiation 5. subject has active or chronic nasal or sinus infection 6. subject has active coagulation disorder or patient is receiving anti-coagulants which cannot be safely stopped for 2 weeks 7. subject has a history of dry nose symptoms 8. subject is pregnant or lactating 9. subject is participating in another clinical research study 10. subject has an allergy or intolerance to anesthetic agent 11. subject is an active smoker or has been a smoker within the last 6 months 12. any physical condition that in the investigator's opinion would prevent adequate study participation or pose increased risk
does an abdominal wall nerve block during surgery help reduce pain from kidney transplantation?

Conditions: Kidney Transplantation

Summary: this is a randomized, placebo controlled, double blind study to determine the effectiveness of a transversus abdominis plane (tap) block for reducing postoperative pain and opioid use in kidney transplant recipients.

the management of post-operative analgesia in kidney transplant recipients is complex secondary to labile fluid shifts and limitations in the use of nsaids secondary to their potential nephrotoxicity. a majority of transplant centers rely on the use of intravenous patient-controlled opioid analgesia as the predominant method of post-operative pain control, however this practice is at odds with the worldwide initiatives to reduce post-operative opioid use and dependence. this study is a single center prospective randomized double blinded study which will compare the post-operative benefits of tap block with liposomal bupivacaine plus free bupivacaine versus placebo (normal saline) tap block in participants receiving both the ars and the gibson incisions for kidney transplantation . approximately 200 participants will be enrolled at the cleveland clinic. the operative approach (i.e. gibson or ars) is at the discretion of the operating surgeon and will proceed in the standard fashion. at the completion of the dissection of the external iliac vessels and prior to bringing the transplant kidney into the field, an intraoperative tap block will be performed by inserting a 22 gauge spinal needle from inside the abdomen into the transversus abdominus plane of the abdominal wall at the lateral superior and inferior border of the surgical dissection and injecting the pre-determined analgesic or placebo. the remainder of the procedure, including the vascular and urinary anastomosis, will proceed identically between the two groups. all participants will receive the same post-operative abdominal surgical dressing. post-operative pain control will follow standard clinical guidelines. all participants will be prescribed on-demand oral oxycodone 5 or 10 mg tablets plus iv morphine or iv dilaudid if needed for severe breakthrough pain. on discharge, all participants will receive ten 5 or 10 mg oxycodone tablets.

Eligibility criteria:
inclusion criteria: - recipients of a single, living or deceased renal transplantation exclusion criteria: * previous renal transplantation on the same side of the body * requiring a native or graft nephrectomy or other additional procedures * urine diversion or augmentation * bowel diversion * recipients of an enbloc pediatric kidney * recipients of a dual kidney transplantation

Keywords: kidney transplant renal transplant post-operative pain
clinical and ultrasound incidence of rheumatologic immune related adverse events in stage iib-iv melanoma patients

Conditions: Melanoma, Stage II; Melanoma Stage III; Melanoma Stage IV

Summary: rheumatologic adverse events are expected to affect between 3% and 7.5% of patients undergoing immunotherapy and are likely to be underdiagnosed. the main aim of this observational prospective study is to investigate the clinical and ultrasonographic incidence of rheumathologic immune related adverse events in a cohort of patients affected by stage iib, iic, iii and iv melanoma undergoing treatment with immune-checkpoint inhibitors. patients will: * receive immune-checkpoint inhibitor therapy, according to disease stage and current national guidelines. * undergo dermatologic visit prior to the start of immune-checkpoint inhibitor therapy and at scheduled follow-ups. * undergo rheumatologic visit prior to the start of immune-checkpoint inhibitor therapy and at scheduled follow-ups. * receive a quality of life questionnaire (european organization for research and treatment of cancer quality of life questionnaire - core 30 version 3.0) prior to the start of immune-checkpoint inhibitor therapy and at scheduled follow-ups.


Eligibility criteria:
inclusion criteria: * adult patients affected by stage iib, iic, iii and iv melanoma who start systemic therapy with immune-checkpoint inhibitors. * signature of the patient consent to the study. exclusion criteria: * patients aged below 18 years of age. * patients who are unable to express consent to the study. * patients with a diagnosis of chronic joint diseases: inflammatory arthritis, arthrosis, microcrystalline arthritis, septic arthritis etc. * systemic diseases with likely joint involvement (inflammatory bowel disease, etc.) * previous treatments with immune-checkpoint inhibitors or previous adjuvant therapy with immune-checkpoint inhibitors.
a study to see whether a nutritional supplement is beneficial for patients with pancreatic cancer

Conditions: Pancreatic Cancer

Summary: this study evaluates a nutritional supplement in the treatment of pancreatic cancer in adults. half of the participants will receive the nutritional supplement, while the other half will receive a placebo.


Eligibility criteria:
inclusion criteria: * patients with a newly diagnosed pancreatic tumor thought to be pancreatic cancer scheduled for resection of the tumor. * patients with a newly diagnosed pancreatic tumor thought to be pancreatic cancer, subsequently found to have biliary or ampullary cancer upon full pathological review, scheduled for resection of the tumor. * patients with a ct image, which includes scans of the 3rd lumbar region, taken within 45 days before tumor resection surgery. * ability to maintain oral intake. * ability to give written, informed consent. exclusion criteria: * patients found to have a diagnosis other than pancreatic, biliary, or ampullary cancer upon full pathological review. * patients with a benign tumor. * patients taking drugs that modify muscle metabolism. * patients with uncontrolled jaundice. * a compliance rate of \<80%, excluding compliance during recovery from tumor resection surgery while in the hospital. * patients currently taking the nutritional supplement being investigated in this study. * patients in the placebo group who have plasma levels of the nutritional supplement components within the range of the nutritional supplement group at study time points when plasma levels of the nutritional supplement components are significantly higher in the nutritional supplement group versus the placebo group. * inadequate specimens. * known allergy to gelatin or glycerin.
short term results of pediatric septic hip arthritis management in assiut university hospitals

Conditions: Septic Arthritis

Summary: detect short term results of pediatric septic hip arthritis and its risk factors

septic arthritis of the hip is a true orthopedic emergency(1). in developed countries, the incidence of acute bacterial septic arthritis is estimated to be 4 to 10 per 100,000 children (2).it is caused by many microorganisms. staph aureus is most common in children over 2 years of age . staph aureus is gram-positive cocci in clusters and most common in nosocomial infections of neonates(3-4).group b streptococcus is most common in neonates with community-acquired infection and exposed during transvaginal delivery(5).neisseria gonorrhoeae is gram-negative diplococci and most common in adolescents.when the causative organism is neisseria gonorrhoeae ,patients usually have a preceding migratory polyarthralgia,multiple joint involvement and small red papules(6-7).group a beta-hemolytic streptococcus is most common organism following varicella infection.hacek organisms (haeophilus,actinobacillus,cardiobacterium,eikenella,and kingella fastidious) are less common causative organisms(8-9).early diagnosis and accurate treatment is key in avoiding complications such as joint destruction,joint dislocation , ankylosis, growth arrest or spread of infection leading to osteomyelitis , pelvic abscess or nerve lesions.. treatment is started without delay after synovial fluid and blood samples have been obtained. the classical presentation of septic hip arthritis in children is a combination of a painful hip joint with limited range of motion, fever, malaise and inability to bear weight on the affected limb. misdiagnosis or inappropriate treatment of acute septic arthritis of the hip in children can result in devastating damage of the joint and possible lifelong disability. open arthrotomy , drainage and thorough irrigation of the joint is considered the standard treatment for septic arthritis of the hip.empiric antibiotic treatment primarily targets s. aureus and takes into account its resistance to antibiotics(10-11). so,we want to detect short term results of pediatric septic hip arthritis at assiut university hospitals

Eligibility criteria:
inclusion criteria: - children younger than 14 years old presented with septic hip arthritis only or by bilateral septic hip arthritis in assiut university hospitals exclusion criteria: * 1-patients with tuberculous arthritis 2-patients whose parents refuse to participate in the study
impact of stigma in siblings of young patients with schizophrenic disorders

Conditions: The Impact of Stigma on the Quality of Life of People With Schizophrenic Disorders and Their Siblings

Summary: impact of stigma on the empathy and quality of life of people with schizophrenic disorders and their siblings.


Eligibility criteria:
inclusion criteria: inclusion criteria for the person with schizophrenic disorder 1. aged between 18 and 35. 2. medical follow-up in progress 3. dsm-5 diagnosis of schizophrenia spectrum disorder 4. reading and understanding the information and non-opposition form 5. person affiliated to a social protection scheme or beneficiary of state medical aid 6. volunteer mastering the french language exclusion criteria: non-inclusion criteria for the person with schizophrenic disorders: 1. clinical condition incompatible with testing 2. current or less than one month's commitment to another research protocol 3. a person who is subject to a safeguard measure of justice 4 a person of full age under guardianship 5. minor patients with mental disorders 6. pregnant or breastfeeding women version 1.2 date 19-05-2020 7. a person in situations of social fragility (persons deprived of liberty by a judicial or administrative decision, hospitalized persons) 8. persons incapable or unable to give consent inclusion criteria: inclusion criteria for a sibling member: 1. age of 16 years or older 2. volunteer with a sibling included in the study with a diagnosis of schizophrenia according to dsm-5. 3. reading and understanding the information and non-opposition form 4. volunteer affiliated to a social protection scheme or beneficiary of state medical aid 5. volunteer mastering the french language criteria for non-inclusion of siblings: 1. clinical condition incompatible with testing 2. current or less than one month's commitment to another research protocol 3. brother or sister subject to a measure of safeguard of justice 4 brother or sister under curatorship 5. brother or sister with mental health problems 6. minor siblings under 16 years of age 7. a pregnant or nursing sister 8. brother or sister in situations of social fragility (persons deprived of liberty by a judicial or administrative decision, hospitalized persons) 9.brother or sister incapable or unable to give consent
myeloid-derived suppressor cells in sepsis

Conditions: Sepsis

Summary: this study is designed for septic patients, to isolate mdscs and the correlation of prognosis of sepsis. the purpose of this study hopes to explore the phenomenon and possible mechanisms of mdscs in patients with severe sepsis.


Eligibility criteria:
inclusion criteria: * patients must have known origin of infection . * systemic inflammatory response syndrome. exclusion criteria: * age less than 18 years * pregnancy * known anaphylactoid reaction to colloid fluids * a life expectancy less than 24 hours, * inability to provide informed, written consent * patients receiving nephrotoxic drugs, * admitted to the hospital following a surgical procedure, * sepsis more than 72 hours when screening .
hypnotherapy in treating chronic pain in cancer survivors

Conditions: Anxiety; Cancer Survivor; Chronic Pain; Depression; Sleep Disorder

Summary: this randomized pilot clinical trial studies hypnotherapy in treating chronic pain in cancer survivors. hypnotherapy is a state of concentration and focused attention which can provide more control over the experience of acute and chronic pain and its impact and may provide comfort, maximize function, and improve quality of life in cancer survivors.

primary objectives: i. to test the feasibility (recruitment, attrition, adherence, logistical issues) of delivering the hypnosis (hypnotherapy) intervention to cancer survivors with chronic pain. ii. to evaluate the acceptability of the hypnosis intervention among cancer survivors with chronic pain. iii. to explore preliminary efficacy (estimate effect size) of hypnosis in relieving pain and improving associated anxiety and functional performance at 4 weeks and 8 weeks compared to a wait-list control. outline: participants are randomized to 1 of 2 groups. immediate intervention group: participants undergo hypnotherapy session over 20-30 minutes using a standardized script for pain reduction that contains post-hypnotic suggestions for permanence of hypnotherapy benefits. the hypnotherapy session is recorded and the participant listens to the recording daily for 4 weeks. wait-list control group: at week 5, participants undergo hypnotherapy session over 20-30 minutes using a standardized script for pain reduction that contains post-hypnotic suggestions for permanence of hypnotherapy benefits. the hypnotherapy session is recorded and the participant listens to the recording daily for 4 weeks.

Eligibility criteria:
inclusion criteria: * self-report of moderate or higher pain on average during the last week (\> 3 on a 0-10 pain intensity numeric scale) * completed active cancer treatment other than maintenance therapy \>= 3 months ago * functional fluency in english * mentally and physically able to participate and complete surveys over the phone exclusion criteria: * chronic pain is not cancer-related
beijing hospital atherosclerosis study

Conditions: Atherosclerosis; Cardiovascular Diseases; Coronary Artery Disease; Myocardial Ischemia; Stroke

Summary: the beijing hospital atherosclerosis study (bhas) is a prospective, single-center, observational cohort study performed at the beijing hospital in beijing, china. subjects enrolled in this study will be the consecutive patients undergoing coronary angiography in the hospital. blood samples are taken immediately before the angiographic procedure. clinical and angiographic characteristics are recorded. all patients will have routine follow-up at 6 months and 1 year postprocedure, then yearly thereafter. follow-up includes mortality, myocardial infarction (mi), stroke, rehospitalization, coronary revascularization procedures, life styles, and medication use. the primary end point for the study will be the major adverse cardiovascular events (mace), defined as death from any cause, nonfatal myocardial infarction, nonfatal stroke and revascularization. this study has been reviewed and approved by the ethics committee of beijing hospital. all enrolled individuals will be received written notice of the intended use of their blood samples and provided written consent. the major objectives of the bhas study are to (1) establish a prospective cohort and a biological sample bank in ethnic chinese with coronary angiography, (2) identify baseline new biosignature profiles such as novel biomarkers via metabolomics approach associated with the subsequent clinical events, (3) assess the use of molecular profiles from multiple platforms (eg, genomics, proteomics, and metabolomics) integrated with readily available clinical information for improved risk classification for cardiovascular events, and (4) provide clearer understanding of underlying disease processes.


Eligibility criteria:
inclusion criteria: * age \>18y * consent for the study * primary reason for catheterization is concern for ischemic heart disease * complete clinical and coronary angiogram data available exclusion criteria: * primary pulmonary hypertension or severe lung disease * cardiac transplantation * other solid organ transplant * peripheral vascular intervention only * right heart catheterization only * advanced heart failure * congenital heart disease * women who are pregnant or nursing, or preparing for pregnant during the study period * progressive fatal disease * history of alcoholism or drug abuse * patients with mental illness and are being treated * patients are undergoing radiotherapy or chemotherapy * acute and chronic infectious diseases

Keywords: atherosclerosis longitudinal biomarker coronary angiography follow-up metabolomics risk factor
capsular outcomes of pediatric cataract surgery with primary intraocular lens implantation

Conditions: Capsular Contracture, Implant; Pediatric Cataract

Summary: lens capsular often changes after pediatric cataract surgery，causing complications such as anterior capsulerhexis shrinkage, visual axis opacification (vao), zonular dehiscence and so on. the aim of study was to prospectively investigate the capsular outcomes of pediatric cataract surgery with primary intraocular lens (iol) implantation.

to investigate the capsular outcomes from a case series of children who underwent cataract surgery and primary iol implantation at the eye hospital of wenzhou medical university between 2016 and 2019. took digital retro-illumination photographs of pediatric eyes at baseline and 6 months, 12 months, and the last visit postoperatively. compare the capsular outcomes of the posterior capsule opening (pco) area and visual axis transparent area at those time points, and analysis the correlations between the pco area and influential factors, such as age at surgery, axial growth, and follow-up duration.

Eligibility criteria:
inclusion criteria: children (age 0.5\~8 years) who underwent cataract surgery, posterior capsulorhexis or capsulotomy and anterior vitrectomyand primary iol implantation at the eye hospital of wenzhou medical university (hangzhou, china). the follow-up period was at least 1 year. exclusion criteria: patients with ocular trauma, corneal disorders, glaucoma, preoperative lens luxation or subluxation, membranous cataract, persistent hyperplastic primary vitreous, surgical or postoperative complications such as glaucoma or suspect-glaucoma and synechia, pupils that could not be sufficiently dilated, and those who could not complete follow-ups or did not have clear digital photographs.

Keywords: capsular outcome pediatric cataract posterior capsulorhexis